Gnekow A K, Kortmann R-D, Pietsch T, Emser A
I. Hospital for Children and Adolescents, Augsburg.
Klin Padiatr. 2004 Nov-Dec;216(6):331-42. doi: 10.1055/s-2004-832355.
Low grade gliomas arise in all CNS-locations and age groups, chiasmatic-hypothalamic tumors occur especially in young children. Early radiotherapy (RT) shall be deferred by chemotherapy (CT) within the concept of the HIT-LGG 1996 study, offering a comprehensive treatment strategy for all age groups.
198 of 905 protocol patients (21.9 %) had a chiasmatic (34), chiasmatic-hypothalamic (144) or hypothalamic (20) primary tumor, median age at diagnosis 3.6 years (0.2-16.3 y.), 54 had neurofibromatosis (27.3 %), 108 female (54.5 %). 98 children had severe visual impairment as their first symptom. The initial neurosurgical intervention resulted in 5 complete, 26 subtotal, 45 partial resections, 67 biopsies; 55 children had a diagnosis on the basis of neuroradiologic findings. Histology showed 132 pilocytic astrocytoma I degrees , 6 astrocytoma II degrees /nos and 2 DIGG/DIA I degrees (3 not known).
82 children were treated at diagnosis, 68 upon clinical or radiological progression following observation times of 3.0 to 115.0 months. RT: 27 children received conventional (18) or interstitial (8) RT (1 not documented) at a median age of 7.3 years; 7 tumors went into further progression. At a median observation time of 50.1 months 21 tumors are stable, 3 regressive (2 not evaluable, 1 death). CT: 123 children received vincristin/carboplatin at a median age of 3.7 years. 105/123 achieved CR/PR/SD. 44/123 tumors were progressive after median 22.5 months, 37 with a chiasmatic-hypothalamic primary, 16/44 were irradiated. At a median observation time of 44.7 months 2 children are in complete remission, 92 tumors are stable, 8 regressive, 9 progressive. 4 children died, 8 are not evaluable. At 60 months overall survival of the cohort is 0.93; PFS of the CT-group is 0.61, the RT-free survival 0.83. Within the CT-group children with an age at diagnosis < 1 year and non-pilocytic histology are at increased risk for early progression. Causative factors cannot be defined, yet.
Within the comprehensive treatment strategy for low grade glioma HIT-LGG 1996 chemotherapy is effective to delay the need for early radiotherapy in chiasmatic-hypothalamic glioma. More effective reduction of the risk for progression has to be sought for young children < 1 year.
低级别胶质瘤可发生于中枢神经系统的所有部位及各年龄组,视交叉 - 下丘脑肿瘤尤其多见于幼儿。在1996年HIT - LGG研究的理念中,早期放疗(RT)应通过化疗(CT)推迟进行,该研究为所有年龄组提供了全面的治疗策略。
905例符合方案的患者中有198例(21.9%)患有视交叉(34例)、视交叉 - 下丘脑(144例)或下丘脑(20例)原发性肿瘤,诊断时的中位年龄为3.6岁(0.2 - 16.3岁),54例患有神经纤维瘤病(27.3%),108例为女性(54.5%)。98名儿童以严重视力障碍为首发症状。初次神经外科干预导致5例全切、26例次全切、45例部分切除、67例活检;55名儿童根据神经影像学检查结果确诊。组织学显示132例毛细胞型星形细胞瘤I级,6例星形细胞瘤II级/未特指,2例弥漫性胶质瘤/弥漫性星形细胞瘤I级(3例情况不明)。
82名儿童在诊断时接受治疗,68名在观察3.0至115.0个月后出现临床或影像学进展时接受治疗。放疗:27名儿童接受了常规放疗(18例)或间质放疗(8例)(1例记录不明),中位年龄为7.3岁;7例肿瘤进一步进展。在中位观察时间50.1个月时,21例肿瘤稳定,3例退缩(2例不可评估,1例死亡)。化疗:123名儿童接受长春新碱/卡铂治疗,中位年龄为3.7岁。105/123例达到完全缓解/部分缓解/疾病稳定。44/123例肿瘤在中位22.5个月后进展,37例为视交叉 - 下丘脑原发性肿瘤,16/44例接受了放疗。在中位观察时间44.7个月时,2例儿童完全缓解,92例肿瘤稳定,8例退缩,9例进展。4例儿童死亡,8例不可评估。该队列60个月时的总生存率为0.93;化疗组的无进展生存率为0.61,无放疗生存率为0.83。在化疗组中,诊断时年龄<1岁且组织学类型非毛细胞型的儿童早期进展风险增加。目前尚无法确定病因。
在低级别胶质瘤的综合治疗策略HIT - LGG 1996中,化疗对于推迟视交叉 - 下丘脑胶质瘤早期放疗的需求是有效的。对于<1岁的幼儿,必须寻求更有效的降低进展风险的方法。